This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

GeneDx To Launch Comprehensive Breast Cancer Genetic Test

Gaithersburg, Md., June 13, 2013 /PRNewswire/ -- GeneDx, one of the world's foremost genetic testing laboratories and a subsidiary of Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) announced today its intention to launch a suite of comprehensive genetic tests for inherited cancers including BRCA1 and BRCA2 genes, given the Supreme Court's ruling in the Association for Molecular Pathology vs. Myriad Genetics case.

GeneDx, which was the first commercial laboratory to utilize next generation sequencing technologies to answer meaningful clinical questions in cardiology, neurology, ophthalmology, among other clinical areas, will now bring its expertise and reputation for service to inherited cancers and will offer a 27-gene panel for breast and ovarian cancers. GeneDx will also provide next generation sequencing based multi-gene panels for gastrointestinal and colorectal cancers, pancreatic cancer, endometrial cancer and renal cell carcinoma. The Company has indicated that it intends to introduce all of these panels as early as August 1, 2013.

According to Sherri Bale, Ph.D., a founder and the Managing Director of GeneDx, "These panels will provide an efficient and cost-effective approach to identifying the genetic basis of inherited cancer. For breast/ovarian cancer particularly, it will be a more sensitive approach than testing only the BRCA1 and BRCA2 genes alone. Over the past decade, research has identified many genes associated with hereditary cancers. Some of these genes play a role in more than one type of cancer, and in most types of cancer several genes may be characterized as causative. Determining which genes and the order in which to test them can be complex, expensive and time consuming. GeneDx, therefore, has developed comprehensive panels to facilitate testing of all the important genes associated with inherited cancers in a manner that provides rapid and accurate results and at typically no additional cost when compared to testing for a single gene."

GeneDx has distinguished itself and gained the trust of the genetics community for its clinical and scientific expertise and experience. Founded in 2000 by geneticists and still managed today by geneticists, GeneDx started offering Whole Exome Sequencing in 2012 to help end the diagnostic odyssey for families who for years have been looking for a molecular diagnosis. Currently, GeneDx offers testing for more than 350 genetic disorders, and has over 30 board-certified geneticists and genetic counselors on staff available to physicians to address their concerns and questions about genetic testing.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs